BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Kidney Health Initiative (KHI) - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kidney Health Initiative (KHI)
X-ORIGINAL-URL:https://khi.asn-online.org
X-WR-CALDESC:Events for Kidney Health Initiative (KHI)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260323T160000
DTEND;TZID=UTC:20260323T170000
DTSTAMP:20260404T124446
CREATED:20250323T231938Z
LAST-MODIFIED:20260209T205937Z
UID:10000002-1774281600-1774285200@khi.asn-online.org
SUMMARY:Advancing the Therapeutic Pipeline in Alport Syndrome
DESCRIPTION:Join the Kidney Health Initiative (KHI) for a mixer focused on the future of Alport syndrome therapies. Alport Syndrome Foundation will share updates from their December 2025 FDA campus meeting focused on ASSENT (Alport Syndrome Surrogate Endpoint Network)\, an international initiative with the goal of identifying surrogate endpoints that can be used in clinical trials to accelerate drug development and bring new therapies to patients with Alport syndrome. This session will highlight the status of the pharmaceutical pipeline in Alport syndrome\, key challenges and opportunities in drug development for this rare genetic kidney disease\, and how this patient organization is partnering with industry at every stage—from preclinical exploration to clinical trial design and patient recruitment. Don’t miss this opportunity to hear the latest insights and connect with others committed to accelerating treatments for the Alport community.
URL:https://khi.asn-online.org/event/advancing-the-therapeutic-pipeline-in-alport-syndrome/
CATEGORIES:Mixer
ATTACH;FMTTYPE=image/jpeg:https://khi.asn-online.org/wp-content/uploads/2025/11/download-1.jpeg
END:VEVENT
END:VCALENDAR